European survey on preanalytical sample handling - Part 2 : Practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples. On behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)
INTRODUCTION: No guideline currently exists on how to detect or document haemolysis, icterus or lipemia (HIL) in blood samples, nor on subsequent use of this information. The EFLM WG-PRE has performed a survey for assessing current practices of European laboratories in HIL monitoring. This second part of two coherent articles is focused on HIL.
MATERIALS AND METHODS: An online survey, containing 39 questions on preanalytical issues, was disseminated among EFLM member countries. Seventeen questions exclusively focused on assessment, management and follow-up actions of HIL in routine blood samples.
RESULTS: Overall, 1405 valid responses from 37 countries were received. A total of 1160 (86%) of all responders stating to analyse blood samples - monitored HIL. HIL was mostly checked in clinical chemistry samples and less frequently in those received for coagulation, therapeutic drug monitoring and serology/infectious disease testing. HIL detection by automatic HIL indices or visual inspection, along with haemolysis cut-offs definition, varied widely among responders. A quarter of responders performing automated HIL checks used internal quality controls. In haemolytic/icteric/lipemic samples, most responders (70%) only rejected HIL-sensitive parameters, whilst about 20% released all test results with general comments. Other responders did not analysed but rejected the entire sample, while some released all tests, without comments. Overall, 26% responders who monitored HIL were using this information for monitoring phlebotomy or sample transport quality.
CONCLUSION: Strategies for monitoring and treating haemolytic, icteric or lipemic samples are quite heterogeneous in Europe. The WG-PRE will use these insights for developing and providing recommendations aimed at harmonizing strategies across Europe.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Biochemia medica - 29(2019), 2 vom: 15. Juni, Seite 020705 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cadamuro, Janne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 30.08.2019 Date Revised 08.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11613/BM.2019.020705 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM298392569 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM298392569 | ||
| 003 | DE-627 | ||
| 005 | 20231225094044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.11613/BM.2019.020705 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0994.xml |
| 035 | |a (DE-627)NLM298392569 | ||
| 035 | |a (NLM)31223259 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cadamuro, Janne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a European survey on preanalytical sample handling - Part 2 |b Practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples. On behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE) |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2019 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: No guideline currently exists on how to detect or document haemolysis, icterus or lipemia (HIL) in blood samples, nor on subsequent use of this information. The EFLM WG-PRE has performed a survey for assessing current practices of European laboratories in HIL monitoring. This second part of two coherent articles is focused on HIL | ||
| 520 | |a MATERIALS AND METHODS: An online survey, containing 39 questions on preanalytical issues, was disseminated among EFLM member countries. Seventeen questions exclusively focused on assessment, management and follow-up actions of HIL in routine blood samples | ||
| 520 | |a RESULTS: Overall, 1405 valid responses from 37 countries were received. A total of 1160 (86%) of all responders stating to analyse blood samples - monitored HIL. HIL was mostly checked in clinical chemistry samples and less frequently in those received for coagulation, therapeutic drug monitoring and serology/infectious disease testing. HIL detection by automatic HIL indices or visual inspection, along with haemolysis cut-offs definition, varied widely among responders. A quarter of responders performing automated HIL checks used internal quality controls. In haemolytic/icteric/lipemic samples, most responders (70%) only rejected HIL-sensitive parameters, whilst about 20% released all test results with general comments. Other responders did not analysed but rejected the entire sample, while some released all tests, without comments. Overall, 26% responders who monitored HIL were using this information for monitoring phlebotomy or sample transport quality | ||
| 520 | |a CONCLUSION: Strategies for monitoring and treating haemolytic, icteric or lipemic samples are quite heterogeneous in Europe. The WG-PRE will use these insights for developing and providing recommendations aimed at harmonizing strategies across Europe | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a preanalytics | |
| 650 | 4 | |a standardization | |
| 650 | 4 | |a survey | |
| 700 | 1 | |a Lippi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a von Meyer, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Ibarz, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a van Dongen, Edmee |e verfasserin |4 aut | |
| 700 | 0 | |a Lases5 |e verfasserin |4 aut | |
| 700 | 1 | |a Cornes, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Nybo, Mads |e verfasserin |4 aut | |
| 700 | 1 | |a Vermeersch, Pieter |e verfasserin |4 aut | |
| 700 | 1 | |a Grankvist, Kjell |e verfasserin |4 aut | |
| 700 | 1 | |a Guimaraes, Joao Tiago |e verfasserin |4 aut | |
| 700 | 1 | |a Kristensen, Gunn B B |e verfasserin |4 aut | |
| 700 | 1 | |a de la Salle, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Simundic, Ana-Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemia medica |d 1997 |g 29(2019), 2 vom: 15. Juni, Seite 020705 |w (DE-627)NLM095507043 |x 1846-7482 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2019 |g number:2 |g day:15 |g month:06 |g pages:020705 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11613/BM.2019.020705 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2019 |e 2 |b 15 |c 06 |h 020705 | ||